Meta-analysis shows superior efficacy compared to drugs of the same mechanism
[팜뉴스=이권구 기자] The anticancer drug’Riboceranib (Chinese name Afatinib)’ was confirmed to be effective in bone sarcoma and soft tissue sarcoma following gastric cancer and adenoid cystic cancer alone.
China’s Air Force Medical School uses meta-analysis (meta-analysis, a research method that collects and re-analyzes data on 827 bone and soft tissue sarcoma patients and 21 related research data published in recent years). It was published in the Swiss medical journal’Frontiers in Oncology’ on the 17th.
In particular, the results of research targeting angiogenesis inhibitors (VEGFR-2 inhibitors) included comparisons of riboseranib, Sorafenib, Pazopanib, and Anlotinib. The clinical subjects were riboseranib in 827, sorafenib in 101, pazopanib in 246, and anrotinib in 166.
Clinical results ORR (objective response rate) was riboseranib 23.85%, sorafenib 14.47%, pazopanib 5.56%, anrotinib 12.65%, DCR (disease control rate) was riboceranib 79.16%, sorafenib 47.36%, and parenib 14.47% Jopanib 72.36%, anrotinib 74%, and PFS (progression free survival) were riboseranib 7.08 months, sorafenib 4.2 months, pazopanib 4.6 months, and anrotinib 5.6 months respectively. Subsequently, it proved that it can be a good treatment alternative for sarcoma.
Regarding the clinical results, a HLB official said, “We will actively review the clinical expansion of various carcinomas such as sarcomas other than solid cancers such as gastric cancer, liver cancer, colon cancer, and adenoid cystic cancer.”
Copyright © Farm News Unauthorized reproduction and redistribution prohibited